Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce F Liu

Showing results (61-70 of 105) with videos related to

Pageof 11
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 24, 2014
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinomaMaria Giuseppina Baratta, Anna C Schinzel, Yaara Zwang, et al.
Cancer Cell|March 16, 2010
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsQing Sheng, Xinggang Liu, Eleanor Fleming, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 4, 2014
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogeneGavin P Dunn, Hiu Wing Cheung, Pankaj K Agarwalla, et al.
Journal for Immunotherapy of Cancer|January 7, 2023
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancerLiya Ding, Qiwei Wang, Antons Martincuks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Gynecologic Oncology|March 9, 2025
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcomaKevin Tyan, Kevin X Liu, Alicia C Smart, et al.
Cell Reports|December 13, 2018
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian CancerLiya Ding, Hye-Jung Kim, Qiwei Wang, et al.
Gynecologic Oncology|August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trialElizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Pageof 11

Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Proceedings of the National Academy of Sciences of the United States of America|December 24, 2014
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinomaMaria Giuseppina Baratta, Anna C Schinzel, Yaara Zwang, et al.
Cancer Cell|March 16, 2010
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsQing Sheng, Xinggang Liu, Eleanor Fleming, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 4, 2014
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogeneGavin P Dunn, Hiu Wing Cheung, Pankaj K Agarwalla, et al.
Journal for Immunotherapy of Cancer|January 7, 2023
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancerLiya Ding, Qiwei Wang, Antons Martincuks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Gynecologic Oncology|March 9, 2025
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcomaKevin Tyan, Kevin X Liu, Alicia C Smart, et al.
Cell Reports|December 13, 2018
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian CancerLiya Ding, Hye-Jung Kim, Qiwei Wang, et al.
Gynecologic Oncology|August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trialElizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Pageof 11